This study evaluated the Medtronic MiniMed Continuous Glucose Monitoring System (CGMS) in patients with type 1 diabetes mellitus who underwent successful islet cell transplantation (ICT). The results are compared to standardized self-monitoring (SMBG) of hyperglycemia and mean amplitude of glycemic excursions (MAGE). We studied 19 patients (mean age 40.0 ± 6.7 years) in three groups: six patients post-ICT, seven patients awaiting ICT, and six normal volunteers (controls). Continuous glucose monitoring post-ICT showed remarkable glucose stability compared with patients awaiting ICT. The CGMS group showed modestly higher glucoses (mean 111.5 mg/dl) compared with controls (88 mg/dl). Postprandial glucoses in ICT recipients rarely exceeded 180 mg/dl and were similar to controls. There was no difference in asymptomatic hypoglycemia between control and post-ICT groups. However, a higher incidence of hypoglycemia was observed in patients awaiting ICT. HbA1c and MAGE pre-and post-ICT were 8.3 ± 0.9% and 6 ± 0.3% ( p < 0.001) and 109 ± 34 and 41 ± 11 ( p < 0.001), respectively. No complications were associated with CGMS. This study suggests ICT significantly improves metabolic control and rate of hypoglycemia when compared with controls and patients awaiting ICT. Similar improvement in metabolic control was observed with SMBG, HbA1c, and MAGE. Although CGMS was not demonstrated to be a superior tool for routine assessment in ICT, it is very helpful in special clinical situations.
INTRODUCTION
A simple and important method of assessing metabolic control on a daily basis is self-monitoring of blood Islet cell transplantation (ICT) has been performed glucose (SMBG) using standard glucose meters. This for more than 20 years (2, 3, 10, 12, 24, (28) (29) (30) (31) . The rate method allows patients and physicians to acquire inof insulin independence at 1 year after transplantation sights about attainment of glucose targets, but is limited reported by the Islet Transplant Registry up to the year due to inability to perform SMBG frequently enough 2000 was 11% (6) . In July 2000 Shapiro and collaborathroughout day and night to identify important blood tors reported a success rate of 100% at 1 year in patients glucose fluctuations. Another important method of asreceiving ICT using a steroid-free immunosuppression sessing metabolic control, which has been shown to regimen (26). ICT has since gained a role as a potential closely correlate with microvascular diabetic complicatreatment for patients with unstable type 1 diabetes meltions, is measurement of levels of glycosylated hemolitus with favorable results being reported from multiple globin (8) . Both SMBG and glycosylated hemoglobin centers throughout the world (1, 11, 16, 17, 27) . Although have been widely used clinically in the management of insulin independence is now an attainable goal following diabetes. Mean amplitude of glycemic excursions (MAGE) ICT, the ability of transplanted islets to normalize meta-(25,26) is yet another measure that quantifies variability bolic control, reverse diabetes, and prevent complicaof blood glucose excursions, and has also been used to tions remains to be validated. assess metabolic control in selected populations.
The development of a method that continuously and ing ultrasound and fluoroscopic guidance (9, 14) . Once access was confirmed, a minimum of 5000 islet equiva-automatically measures glucose levels was a substantial advance to the field of blood glucose monitoring. The lent (IEQ)/kg were infused using the bag method (4). Five patients required two islet transplant infusions Continuous Glucose Monitoring System (CGMS) developed by Medtronic MiniMed was the first system for to achieve insulin independence; one patient required a single infusion. Immunosuppressive regimen consisted continuous ambulatory glucose monitoring approved by the US Food and Drug Administration (FDA) in 1999 of induction with daclizumab and maintenance with sirolimus and tacrolimus (1) . The metabolic data and dem- (18) . The CGMS is comprised of a pager size monitor connected to a glucose-oxidase-based sensor that records ographic characteristics of group 1 patients are outlined in Table 1 . interstitial glucose levels between a range of 40 and 400 mg/dL every 5 min, providing a glycemic profile over a Group 2 patients had type 1 diabetes mellitus for 32.7 ± 11.8 years and were on intensive insulin treat-72-h period and yielding on average 288 readings a day. It helps to define 24-h glycemic profile and identify ment (IIT) (either multiple daily injections or insulin pump), and were awaiting ICT at our institution (Ta-trends that might not be apparent from SMBG, MAGE, and HbA1c. Since its approval, a number of studies have ble 1). Group 3 patients were nondiabetic controls, matched been published addressing the applicability of this device in helping the monitoring and management of gly-for age, sex, and BMI to group 1 patients. They underwent an oral glucose tolerance test (OGTT) to exclude cemic control in patients with diabetes (5, 7, 23, 32) , but reports on its use in the assessment of glycemic excur-diabetes or impaired glucose tolerance; HbA1c levels were also measured. Their demographic data is outlined sions of ICT recipients are limited (13).
The aims of this study were to use CGMS to evaluate in Table 1 . postprandial hyperglycemia and undetected hypoglyce-Procedure mia (blood glucose <60 mg/dl) in patients with type 1
The Medtronic MiniMed (Northridge, CA) CGMS was diabetes mellitus who have achieved insulin indepenused for measuring interstitial fluid glucose concentradence following successful ICT and to compare these tions, which was calibrated to reflect capillary blood results with patients with type 1 diabetes mellitus receivglucose on the Precision Xtra (MediSense, USA) with ing intensive insulin treatment, as well as with nondiaa measurement error of 3.8-5.2%. Patients were inbetic control patients. We also compared CGMS to the structed on the use of the CGMS and asked to enter more traditional ways of assessing metabolic control at least four SMBG values into the CGMS monitor for (SMBG, glycosylated hemoglobin, and MAGE) and atcalibration and correlation purposes, and to keep a detempted to establish if CGMS can offer important intailed written log of food intake, exercise, insulin adminsights in the follow-up and appropriate management of istration, and hypoglycemic events. After 3 days, partici-ICT recipients.
pants either returned to our institution to have the sensor removed or had the sensor removed locally and returned RESEARCH DESIGN AND METHODS it by mail. The information was downloaded using Med-Study Population tronic MiniMed Solution Software version 3.0 A. Pa-The study consisted of three groups: group 1 had six tients were questioned regarding problems with the use patients with type 1 diabetes mellitus rendered insulin of the device. independent after receiving ICT; group 2 had seven pa-Patients in group 1 were evaluated at 6 and 12 tients with insulin-dependent type 1 diabetes mellitus months post-ICT after achieving insulin independence treated with intensified insulin therapy; group 3 had six (five patients after second islet infusion and one after nondiabetic patients who were represented as normal first infusion). Patients in groups 2 and 3 were evaluated controls. Patients' (groups 1 and 2) inclusion criteria inonly once when their condition was otherwise stable. At cluded age between 18 and 65 years, type 1 diabetes 16 months posttransplant two patients were also reevalumellitus for longer than 5 years, negative C-peptide ated with CGMS. (<0.1 pmol/ml or <0.3 ng/ml) in response to a mixed HbA1c levels were measured by high-pressure liquid meal challenge test, absence of autonomic response to chromatography (HPLC) method (Bio-Rad Laboratories hypoglycemia (<54 mg/dl), body mass index (BMI) <26, Diagnostic Group, Hercules, CA). SMBG values were weight <80 kg, and stable diabetes complications. All entered into the Humalink TM system (computerized reparticipants signed a consent form approved by the Unimote telephone access database) that calculated MAGE versity of Miami Institutional Review Board.
values. Group 1 patients received cultured human islet cells RESULTS isolated from brain-dead multiorgan donors utilizing standard protocols (11, 15, (20) (21) (22) . The percutaneous trans-
The scatter plot of the n paired sensor and meter readings displays an exceptional agreement between the hepatic approach was used to gain portal vein access us- paired readings, showing a correlation coefficient of nificance. Postprandial blood glucose values were mostly below 140 mg/dl and showed a profile similar to that 0.85 (n = 436) ( Fig. 1). Figures 2, 3, 4, and 5 show the 24-h profile of the first day of CGMS placement in the observed in the control group; only rarely did postprandial glucose levels exceeded 180 mg/dl in the ICT patient (which began at noon following insertion and calibration of the device), 6 and 12 months following group. Four of the six patients with type 1 DM had many values above 240 mg/dl, including rarely some ICT, in patients with type 1 DM treated with IIT, and in normal patients, respectively. above 300 mg/dl. The blood sugar ranges recorded with CGMS were Continuous glucose monitoring tracings for patients post-ICT at 6 and 12 months ( Figs. 2 and 3) , respec-40-215 mg/dl and 49-243 mg/dl at 6 and 12 months post-ICT in group 1 patients. In groups 2 and 3 the tively, revealed remarkable glucose stability compared with patients with type 1 DM ( Fig. 4 ) on intensive insu-ranges were 40-400 and 40-153 mg/dl, respectively. After ICT (at 6 and 12 months) patients spent most lin regimen. ICT recipients had blood glucose profiles very similar to control patients ( Fig. 5 ), although their of the day (61% and 59%, respectively) with blood glucoses between 61 and 120 mg/dl, showing a pattern that mean blood glucose levels were modestly higher (112 ± 29 and 111 ± 23 mg/dl for 6 and 12 months after ICT, was quite similar to that of nondiabetic controls (Fig. 6) .
In contrast, patients with type 1 DM spent only 36% of respectively) compared with 88 ± 18 mg/dl in normal subjects. These differences did not reach statistical sig-the day within the 61-120 mg/dl target range. ICT patients had, on average, 0.9 episodes of blood glucose <60 mg/dl but greater than 40 mg/dl in 72 h; 70% of these episodes occurred during the day and lasted on average 37 min and 30% occurred during the night and lasted on average 60 min. All episodes were asymptomatic and did not required treatment. Normal patients had on average 1.3 episodes of blood glucose <60 mg/ dl but greater than 40 mg/dl; 77% of these occurred during the day lasting on average 40 min, and 23% during the night lasting on average 20 min ( Fig. 7A and B) . There was no difference in the incidence of blood glucose levels below 60 mg/dl between control and patients following ICT, but we observed a significantly higher incidence in type 1 DM patients on intensive treatment. Comparison of HbA1c values pre-ICT and 12 months post-ICT showed significant improvement, from 8.3 ± Figure 1 . Correlation between CGMS and blood glucose 0.9% to 6 ± 0.3% (p < 0.001), which was slightly higher meters. MAGE, which reflects glycemic stability, showed before CGMS placement.
No major complaints were reported by the patients re-a significant improvement after ICT, decreasing from 109 ± 34 to 41 ± 11 (p < 0.001) after 1 year of ICT.
garding the use of the device other than occasional minor local bleeding and itching at the insertion site after intro-CGMS performed 16 months posttransplant in two ICT patients revealed a significant change in metabolic duction of the sensor. Patients reported limitations in a few activities such as swimming and contact sports; how-stability ( Fig. 8 ). Both patients (patients 3 and 4) subsequently required supplemental insulin (15 and 12 U/day, ever, general daily activities were not affected. respectively). Self-monitoring of blood glucose failed to DISCUSSION reveal the degree of metabolic instability uncovered with CGMS, although most of the SMBG values were above ICT has been performed for over 20 years, with connormal limits. The fasting SMBG averaged 141 mg/dl siderable improvements in graft survival and wider recognition as a potential clinical application over the past 3 years. One of the main goals of ICT is to restore metabolic control to its normal levels. However, it is well known that the islet mass transplanted from one or two donors is below that of a normal pancreas, and consequently ICT recipients may not be expected to achieve a totally normal blood glucose profile but rather to attain a more stable glycemic control. Despite a lack of consensus as to the glycemic targets for patients after ICT, many centers consider acceptable fasting and preprandial blood glucose values ≤140 mg/dl and postprandial values ≤180 mg/dl. While these goals do not correspond to the strictest recommendations of the American Diabetic Association guidelines, we also observed that type 1 DM patients receiving ICT significantly improved HbA1c, MAGE, and hypoglycemia unawareness reactions. Continuous glucose monitoring results in our patients were in the target glycemic range at 6 and 12 months post-ICT, reinforcing the data provided by the SMBG and MAGE. There has been concern that ICT recipients could be 82 GEIGER ET AL. more prone to hypoglycemia due to defective counter-seen in normal controls. However, this improvement in metabolic control could have been predicted from stan-regulatory hormone production (19) . However, we did not find that hypoglycemia is of concern in this popula-dardized clinical assessment provided by traditional methods, such as self-monitoring of blood glucose, tion as assessed by CGMS because the frequency and duration of hypoglycemic episodes were similar to non-HbA1c levels, and MAGE. CGMS did however provide a display of glycemic stability throughout consecutive diabetic patients and no symptoms of hypoglycemia were reported by patients receiving ICT and therefore 24-h periods in successful ICT patients and captured kinetic evidence for glycemic variability that is not other-no treatment was needed. Kessler and colleagues (13) recently reported the use of CGMS in patients receiving wise available. With future evaluation in a larger number of patients, CGMS may prove helpful in identifying simultaneous pancreas/kidney transplantation or pancreatic islet transplantation after kidney grafting. They con-early graft failure. cluded that CGMS was useful to confirm that islet trans- 
